Eansor Norman David 4

Accession 0000914190-21-000405

CIK 0000842023other

View on SEC.gov Company Profile

Filed

Nov 15, 7:00 PM ET

Accepted

Nov 16, 4:51 PM ET

Size

46.2 KB

Accession

0000914190-21-000405

Insider Transaction Report

Form 4

Period: 2021-11-12

BIO-TECHNE CorpTECH

EANSOR N DAVID

SVP - Novus Biologicals

Transactions

Exercise/Conversion
Common Stock
2021-11-12$125.05/sh+27,159$3,396,233→ 28,477 total
Sale
Common Stock
2021-11-12$504.14/sh−537$270,725→ 26,740 total
Sale
Common Stock
2021-11-12$504.09/sh−700$352,860→ 27,777 total
Sale
Common Stock
2021-11-12$502.99/sh−300$150,897→ 27,277 total
Sale
Common Stock
2021-11-12$505.00/sh−400$202,002→ 26,340 total
Sale
Common Stock
2021-11-12$502.77/sh−4,054$2,038,221→ 22,286 total
Sale
Common Stock
2021-11-12$503.61/sh−9,043$4,554,137→ 13,243 total
Exercise/Conversion
Common Stock
2021-11-16$125.05/sh+799$99,915→ 2,117 total
Exercise/Conversion
Stock Options (Right to Buy)
2021-11-12−27,159→ 799 total
Exercise: $125.05Exp: 2024-08-09→ Common Stock (27,159 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2021-11-16−799→ 0 total
Exercise: $125.05Exp: 2024-08-09→ Common Stock (799 underlying)
Sale
Common Stock
2021-11-12$505.49/sh−2,535$1,281,407→ 1,719 total
Sale
Common Stock
2021-11-12$506.24/sh−401$203,002→ 1,318 total
Sale
Common Stock
2021-11-12$504.78/sh−200$100,956→ 27,577 total
Sale
Common Stock
2021-11-12$504.39/sh−8,989$4,533,985→ 4,254 total

Holdings

Restricted Stock Units
→ Common Stock (3,151 underlying)
3,151
Stock Options (Right to Buy)
Exercise: $190.41Exp: 2026-08-07→ Common Stock (21,265 underlying)
21,265
Stock Options (Right to Buy)
Exercise: $177.32Exp: 2025-08-08→ Common Stock (18,066 underlying)
18,066
Stock Options (Right to Buy)
Exercise: $190.41Exp: 2026-08-07→ Common Stock (15,948 underlying)
15,948
Stock Options (Right to Buy)
Exercise: $267.87Exp: 2027-08-05→ Common Stock (11,488 underlying)
11,488
Stock Options (Right to Buy)
Exercise: $267.87Exp: 2027-08-05→ Common Stock (15,318 underlying)
15,318
Stock Options (Right to Buy)
Exercise: $267.87Exp: 2027-08-05→ Common Stock (24,975 underlying)
24,975
Restricted Stock Units
→ Common Stock (1,556 underlying)
1,556
Stock Options (Right to Buy)
Exercise: $177.32Exp: 2025-08-08→ Common Stock (13,550 underlying)
13,550
Restricted Stock Units
→ Common Stock (2,575 underlying)
2,575
Stock Options (Right to Buy)
Exercise: $267.87Exp: 2027-08-05→ Common Stock (24,975 underlying)
24,975
Stock Options (Right to Buy)
Exercise: $481.82Exp: 2028-08-06→ Common Stock (6,080 underlying)
6,080
Stock Options (Right to Buy)
Exercise: $481.82Exp: 2028-08-06→ Common Stock (8,107 underlying)
8,107

Footnotes (20)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F10]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
[F11]Fully exercisable.
[F12]Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
[F13]Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
[F14]Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
[F15]Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
[F16]Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
[F17]Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
[F18]Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
[F19]Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F20]Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file

4
edgar.xmlPrimary
PRIMARY DOCUMENT

Issuer

BIO-TECHNE Corp

CIK 0000842023

→

Entity typeother

Related Parties

filerCIK 0001270905

Filing Metadata

Form type: 4
Filed: Nov 15, 7:00 PM ET
Accepted: Nov 16, 4:51 PM ET
Size: 46.2 KB

View on SEC.gov